Martin Fan
Stock Analyst at Wedbush
(4.98)
# 166
Out of 5,182 analysts
30
Total ratings
69.23%
Success rate
94.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Reiterates: Outperform | $38 | $6.20 | +512.90% | 3 | May 1, 2026 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | $8 → $10 | $4.41 | +126.76% | 3 | Apr 29, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Neutral | $70 → $95 | $86.46 | +9.88% | 2 | Apr 21, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Outperform | $45 → $85 | $62.58 | +35.83% | 4 | Apr 15, 2026 | |
| SANA Sana Biotechnology | Maintains: Outperform | $6 → $7 | $3.27 | +114.07% | 3 | Apr 14, 2026 | |
| VOR Vor Biopharma | Maintains: Neutral | $9 → $15 | $13.85 | +8.30% | 2 | Mar 31, 2026 | |
| ANAB AnaptysBio | Maintains: Outperform | $60 → $75 | $66.76 | +12.34% | 6 | Mar 12, 2026 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $5.21 | +187.91% | 1 | Feb 9, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Outperform | $45 | $19.36 | +132.44% | 3 | Dec 22, 2025 | |
| IMA ImageneBio | Assumes: Underperform | $2 | $5.66 | -64.66% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $10.80 | +112.96% | 2 | Oct 17, 2025 |
Cartesian Therapeutics
May 1, 2026
Reiterates: Outperform
Price Target: $38
Current: $6.20
Upside: +512.90%
Aclaris Therapeutics
Apr 29, 2026
Maintains: Outperform
Price Target: $8 → $10
Current: $4.41
Upside: +126.76%
Nektar Therapeutics
Apr 21, 2026
Maintains: Neutral
Price Target: $70 → $95
Current: $86.46
Upside: +9.88%
Oruka Therapeutics
Apr 15, 2026
Maintains: Outperform
Price Target: $45 → $85
Current: $62.58
Upside: +35.83%
Sana Biotechnology
Apr 14, 2026
Maintains: Outperform
Price Target: $6 → $7
Current: $3.27
Upside: +114.07%
Vor Biopharma
Mar 31, 2026
Maintains: Neutral
Price Target: $9 → $15
Current: $13.85
Upside: +8.30%
AnaptysBio
Mar 12, 2026
Maintains: Outperform
Price Target: $60 → $75
Current: $66.76
Upside: +12.34%
Zura Bio
Feb 9, 2026
Initiates: Outperform
Price Target: $15
Current: $5.21
Upside: +187.91%
Zenas BioPharma
Dec 22, 2025
Reiterates: Outperform
Price Target: $45
Current: $19.36
Upside: +132.44%
ImageneBio
Nov 25, 2025
Assumes: Underperform
Price Target: $2
Current: $5.66
Upside: -64.66%
Oct 17, 2025
Maintains: Outperform
Price Target: $18 → $23
Current: $10.80
Upside: +112.96%